[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-and-flutter\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-and-flutter":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100351976","phase-4-the-danish-warfarin-dialysis-study---safety-and-efficacy-of-warfarin-in-patients-with-atrial-fibrillation-on-dialysis-100351976",false,"NCT03862859","The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis","The Danish Warfarin-Dialysis Study: Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis - A Nationwide Parallel-group Open Randomized Clinical Trial","DANWARD","Inclusion Criteria:\n\n* Patients ≥18 years on chronic dialysis due to end-stage renal disease\n* Non-valvular paroxysmal, persistent, or permanent atrial fibrillation OR non-treated (for \\>2 months) prevalent paroxysmal, persistent or permanent atrial fibrillation as documented by an electrocardiogram or an episode of ≥30 seconds on Holter monitor, or episodes ≥ 6 minutes on event recorders or any other recording device.\n* Competence to understand the study rationale, including potential risks and benefits associated with treatment, necessary for written informed consent.\n\nExclusion Criteria:\n\n* CHA2DS2-VASc Score ≤1\n* Other indications for oral anticoagulation treatment (pulmonary embolism \\\u003C 6 months, deep vein thrombosis \\\u003C3 months, mechanical heart valve prosthesis) irrespective of whether treatment is implemented\n* Ongoing dual antiplatelet treatment\n* Malignancy (with exception of non-melanoma skin cancer) with recent \\\u003C 1 year, ongoing, or planned curative, or palliative chemo- , radiation-, and\u002For scheduled surgical therapy\n* Endoscopy with gastrointestinal ulcer \\\u003C1 month\n* Esophageal varices\n* Autoimmune og genetic coagulation disorders\n* Congenital alactasia, Lapp Lactase deficiency or glucose-galactose malabsorption\n* Pending spinal tap\n* Cerebrovascular malformations\n* Arterial aneurysms\n* Ulcers or wounds (Wagner grad \\>1)\n* Bacterial endocarditis \\\u003C 3 months\n* Active bleeding contraindicating anticoagulation\n* Any non-elective and\u002For non-ambulant surgery \\\u003C7 days\n* Cerebral hemorrhage \\\u003C4 weeks\n* Thrombocytopenia (platelet count \\\u003C100 × 109\u002FL) \\\u003C30 days.\n* Severe liver insufficiency (spontaneous international normalized ratio \\>1.5) \\\u003C30 days.\n* Known intolerance to warfarin\n* Use of hypericum perforatum \u002F St. John's Wort\n* Uncontrolled hypertension (repeat blood pressure \\>180\u002F110 mmhg) \\\u003C 30 days\n* Uncontrolled hyperthyroidism (thyroid-stimulating hormone \\\u003C0.1μIU\u002FmL) \\\u003C30 days\n* Pregnancy or lactation\n* Participation in other ongoing intervention trials adjudged to influence study outcomes","ALL","18 Years",{"count":20,"type":21},718,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The study aims to evaluate the appropriateness of initiating oral anticoagulation for stroke risk reduction in dialysis populations with atrial fibrillation. Specifically, the study will assess the overall safety, tolerability, and efficacy of initiating treatment with Warfarin in patients with end-stage renal disease on dialysis and atrial fibrillation.",[27,28,29,30],"Atrial Fibrillation and Flutter","Stroke","Major Bleed","End-stage Renal Disease","RECRUITING","2026-05-17",{"date":34,"type":35},"2026-05-19","ACTUAL",{"date":37,"type":35},"2019-10-09",{"date":39,"type":21},"2027-01",{"name":41,"class":42},"Nicholas Carlson","OTHER",13,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100560985","multimodal-cardiac-imaging-registry-in-patients-with-atrial-fibrillation-100560985","NCT06584266","Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation","Multimodal, Multicentre Registry of Clinical and Imaging Data to Develop Predictive Models Based on Artificial Intelligence to Support the Diagnostic and Therapeutic Process for Patients with Atrial Fibrillation Undergoing Catheter Ablation and Cardioversion.","IMAGE-AF","Inclusion Criteria:\n\n\\- All patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period (all consecutive patients).\n\nExclusion Criteria:\n\nAge\\<18, lack of informed, written consent to the TEE",{"count":53,"type":21},3000,"12 Months","OBSERVATIONAL","The goal of this observational registry is to collect a curated dataset of multimodal imaging data that will serve for development of artificial-intelligence based solutions for prediction of risk and outcomes in patients with atrial fribrillation.\n\nType of study: observational study\n\nStudy Participants: Patients with atrial fibrillation or atrial flutter who undergo clinically indicated transesophageal echocardiography before catheter ablation or cardioversion.\n\nWe hypothesize, that automatic analysis of video images of transthoracic echocardiography with deep learning combined with clinical data can predict the presence of left atrial appendage thrombus (LAT). Therefore, our main aim is to create and validate an artificial intelligence model to predict the presence of LAT based on automatic analysis of transthoracic echocardiography with artificial intelligence.",[27,58,59,60],"Heart Failure","Artificial Intelligence (AI)","Echocardiography",[62,63,64,65,66,67],"artificial intelligence","left atrial thrombus","transesophageal echocardiography","left atrial appendage thrombus","ablation","left atrial function","2024-08-31",{"date":70,"type":35},"2024-09-04",{"date":72,"type":35},"2024-01-01",{"date":74,"type":21},"2027-09",{"name":76,"class":42},"University in Zielona Góra",7,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100530467","impact-of-education-level-on-clinical-outcomes-in-self-inr-managed-patients-100530467","NCT06187155","Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients","Impact of Education Level on Clinical Outcomes in Self-INR Managed Patients on Longterm Warfarin: a Single-center Randomized Controlled Study","Inclusion Criteria:\n\n* Adult patients above 18 years who are indicated for long term VKA and has been on VKA for more than 6 months.\n\nExclusion Criteria:\n\n1. Refusal to join the study.\n2. History of prior life-threatening bleeding or thrombo-embolic events.\n3. Illiterate patients with no caregivers living at the same home.",{"count":86,"type":21},586,[88],"NA","Oral anticoagulation (OAC) is indicated in a wide variety of clinical conditions including atrial fibrillation (AF), mechanical valve prosthesis (MVP), deep vein thrombosis and pulmonary embolism. Although direct OAC has replaced vitamin K antagonists (VKA) in non-valvular AF due to lower bleeding risk, it's still recommended to use VKA specifically in cases of valvular AF, MVP and anti-phospholipid syndrome.\n\nVKA has a narrow therapeutic range and multiple drug interactions causing unpredicted pharmacodynamics. This requires regular monitoring of the international normalized ratio (INR) level to ensure it's in the target therapeutic range and prevent extreme values that may result in thrombo-embolic events or sometimes fatal bleeding.\n\nSelf-INR monitoring and management have emerged recently as a safe cost-effective alternative to standard management, with evidence of tighter control of INR, reduction of thrombo-embolic events, and improving treatment-related quality of life. However, there are no specific criteria for patient selection. Whether the level of education and other social factors would affect the outcomes of self-management is still not clear.\n\nOwing to the wide geographical area served by Aswan Heart Center, many patients have to cover long distances to follow up their INR and seek medical advice regarding adequate dose modification. This may result in reluctance and non-compliance to clinic visits and INR testing. Proper education, training and providing an alternative near place to measure the INR and self-adjust warfarin dose is expected to improve patient adherence and compliance.",[27,91],"Mechanical Mitral Valve Prosthesis",[93,94,95,96],"INR self-management","education level","warfarin","time in therapeutic range",{"date":98,"type":35},"2024-09-05",{"date":100,"type":35},"2023-12-01",{"date":102,"type":21},"2024-12-01",{"name":104,"class":42},"Cairo University",1]